![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
News
High Purity New England Supports Drug Development Pipelines with Fully Customizable and Flexible Single-Use Assembly Solution
Demand for single-use assembly solutions in the biopharma industry continues to increase, with the market expected to be worth $26.89 billion by 2025.
To help...
News
Sterling Pharma Solutions acquires API facility in the US
Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions, has announced its acquisition of Alcami’s Germantown, Wisconsin facility in the US.
The new facility...
News
BD Announces CE Mark of Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes
BD (Becton, Dickinson and Company), a leading global medical technology company, announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™...
News
Regenerative Medicine Market Rapidly Growing Worldwide at Healthy CAGR
As per the Organ Procurement and Transplantation Network, 36,527 organ transplants were accomplished in the United States in 2020. Regenerative medicines plays a vital...
Clinical Trials
Innovent phase 3 ORIENT-32 trial of Tyvyt in combo with Byvasda to treat advanced hepatocellular carcinoma meets primary endpoints
Innovent Biologics, a biopharmaceutical company, announced the results of a phase 3, open label, randomized study in China. The ORIENT-32 trial evaluating Tyvyt (sintilimab...
News
CPhI Pharma Index: Italy and India the only pharma economies to improve score in 2020
Ahead of the CPhI Festival of Pharma (5-16 October, 2020) – global pharma’s largest ever virtual gathering – the CPhI Pharma Index shows only...
Clinical Trials
Anti-influenza drug Avigan Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients
FUJIFILM Toyama Chemical Co., Ltd. has announced that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” conducted in Japan...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read